Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 7630)

INSIDE INFORMATION
APPROVAL BY THE EUROPEAN COMMISSION FOR MARKETING OF SENAPARIB

This announcement is made by IMPACT Therapeutics, Inc (the "**Company**" and together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce that the European Commission (EC) has granted approval for Senaparib (Chinese trade name: 派舒寧®; overseas trade name: Sepalna®), a self-developed innovative drug for the maintenance treatment of advanced epithelial ovarian, fallopian tube and primary peritoneal cancer. The approval by the European Commission (EC) follows the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Senaparib becomes the first China-developed, first-line maintenance treatment PARP inhibitor approved in the Europe for the all-comer population of advanced ovarian cancer, marking another breakthrough for a China-developed innovative targeted therapy for ovarian cancer in the European market.

About Senaparib (IMP4297)

Senaparib (Sepalna®) is a novel, highly potent PARP1/2 inhibitor independently developed by the Company. Its unique molecular structure ensures excellent target selectivity and a wide safety window. Senaparib capsules received National Medical Products Administration of China approval in January 2025 as a first-line maintenance therapy for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer achieving complete or partial response to platinum-based chemotherapy, and has been subsequently included in the National Reimbursement Drug List in December 2025. The Company is actively advancing the clinical and regulatory development of senaparib globally. Concurrently, the Company is pursuing life cycle management for senaparib, exploring combination therapy opportunities, and expanding into multiple indications.

About Ovarian Cancer (OC)

OC is one of the most lethal malignancies affecting women, with a mortality rate that ranks among the highest for female cancers. OC patients typically receive 1L systemic therapy upon diagnosis. Following completion of initial treatment, patients who achieve complete or partial response generally enter the 1L maintenance phase as part of the standard treatment paradigm. As such, 1L maintenance therapy represents the largest and most broadly applicable treated population within the overall OC patient pool. The global and China OC drug markets have experienced rapid growth, driven primarily by 1L maintenance therapy and later-line BRCAmut treatments, with 1L maintenance accounting for the largest share of market demand.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

Cautionary Statement required by Rule 18A.05 of the Listing Rules: The Company cannot guarantee that senaparib will be ultimately marketed in the licensed territories. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
IMPACT Therapeutics, Inc
南京英派藥業股份有限公司
Dr. Sui Xiong CAI
Executive Director and Chief Executive Officer

Hong Kong, November 17, 2026

As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive Directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive Directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as independent non-executive Directors.